UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000003915
Receipt No. R000004706
Scientific Title Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancer
Date of disclosure of the study information 2010/07/14
Last modified on 2017/01/13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancer
Acronym Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancer(KSCC0902)
Scientific Title Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancer
Scientific Title:Acronym Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancer(KSCC0902)
Region
Japan

Condition
Condition Colorectal Cancer
Classification by specialty
Gastroenterology Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To evaluate the efficacy and the safety of XELOX/Bevacitumab as a first line chemotherapy for the patients with unresectable or recurrent colorectal cancer
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2 Pragmatic
Developmental phase Phase IV

Assessment
Primary outcomes Response rate
Key secondary outcomes Progression free survival
Time to tretment failure
Time to failure of strategy
Overall survival
Safety
Quality of life

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Oxaliplatin 130mg/m2 i.v. (day1)
Bevaciumab 7.5mg/Kg i.v. (day1)
Capecitabine X2,000mg/m2, p.o.(day1-14)
to be repeated every 3 weeks
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1.Written informed consent
2.Appropriate for the study at the physician's assessment
3.Histologically confirmed adenocarcinoma of the colon or rectum.
4.No prior chemotherapy for the patients with unresectable or recurrent colorectal cancer
5.Prior adjuvant chemotherapy is allowed if it is completed at least 2 weeks before registration.
6.No prior radiotherapy for target lesion.
7.Aged 20<= years.
8.ECOG performance status of 0-2.
9.At least one measurable lesion based on the RECIST criterion. (within 28 days before registration)
10.Life expectancy at least 3 months.
11.Required baseline laboratory parameters (within 14 days before registration):
WBC more than 3000 and WBC less than 12000/mm3
Neu more than 1,500/ mm3
Plt more than 100,000/ mm3
Hb more than 9.0g/dl
T-Bil less than 2.0mg/dl
AST,ALT within 2.5 times of normal limit of each hospital(in case of hepatic metastatic patients are within 5.0 times of normal limit )
Cre less than 1.5mg/dl
Urinary protein less than grade1 (+1 or 0.15-1.0g/24h)
Key exclusion criteria 1.Co-mobility, such as infection, heart failure, history of cardiac infarction, liver cirrhosis, viral hepatitis type B , jaundice, kidney failure, uncontrolled hypertension, diabetes, interstitial lung disease, lung fibrosis, pulmonary emphysema.
2.Coelomic fluid which need therapy( pleural effusion, abdominal dropsy, pericardial fluid)
3.History of the severe hypersensitivity
4.Active other malignancies.
5.History of mental disorder, central nerve disorder, cerebral vascular disorder.
6.Brain metastasis
7.Evidence of bleeding diathesis, intestinal paralysis , ileus, peptic ulcer, traumatic bone fracture
8.Watery stools or Grade 2 or more diarrhea
9.Surgical procedure within 4 weeks before registration (implantation of the central venous port within 1 week before registration.)
10.Requiring anti-thrombogenic therapy to prevent thrombosis
11.Requiring immunosuppressive drug or steroid drug
12.Pregnant or lactating woman
13.Not appropriate for the study at the physician's assessment
Target sample size 41

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Kazuo Shirouzu
Organization Kurume University School of Medicine
Division name Department of Surgery Medicine
Zip code
Address 67 Asahimachi, Kurume City, 830-0011, Japan
TEL 092-631-2920
Email kscc2@cres-kyushu.or.jp

Public contact
Name of contact person
1st name
Middle name
Last name KSCC
Organization CLinical Research Support Center Kyushu
Division name KSCC
Zip code
Address 3-1-1, Maidashi, Higashi-Ku, Fukuoka, Japan, 812-8582
TEL 092-631-2920
Homepage URL
Email kscc2@cres-kyushu.or.jp

Sponsor
Institute Kyushu Study group of Clinical Cancer
Institute
Department

Funding Source
Organization Clinical Research Support Center Kyushu
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 九州大学(福岡県)
貝塚病院(福岡県)
国立病院機構九州医療センター(福岡県)
国立病院機構九州がんセンター(福岡県)
公立学校共済組合九州中央病院(福岡県)
済生会福岡総合病院(福岡県)
福岡歯科大学医科歯科総合病院(福岡県)
済生会八幡総合病院(福岡県)
新日鐵八幡記念病院(福岡県)
国立病院機構福岡東医療センター(福岡県)
社会保険田川病院(福岡県)
社会保険仲原病院(福岡県)
久留米大学(福岡県)
久留米大学医療センター(福岡県)
社会保険久留米第一病院(福岡県)
聖マリア病院(福岡県)
公立八女総合病院(福岡県)
飯塚病院(福岡県)
宗像医師会病院(福岡県)
福岡市民病院(福岡県)
新小文字病院(福岡県)
福岡大学(福岡県)
福岡大学筑紫病院(福岡県)
済生会唐津病院(佐賀県)
有田共立病院(佐賀県)
健康保険諫早総合病院(長崎県)
佐世保市立総合病院(長崎県)
白十字会 佐世保中央病院(長崎県)
長崎大学(長崎県)
春回会 井上病院(長崎県)
光晴会病院(長崎県)
医理会 柿添病院(長崎県)
長崎百合野病院(長崎県)
熊本大学(熊本県)
高野会 高野病院(熊本県)
済生会熊本病院(熊本県)
熊本赤十字病院(熊本県)
熊本中央病院(熊本県)
健康保険人吉総合病院(熊本県)
健康保険八代総合病院(熊本県)
荒尾市民病院(熊本県)
大分赤十字病院(大分県)
国立病院機構大分医療センター(大分県)  
国立病院機構別府医療センター(大分県)
中津市立中津市民病院(大分県)
大分県立病院(大分県)
大分県済生会日田病院(大分県)
潤愛会 鮫島病院(鹿児島県)
鹿児島大学(鹿児島県)
鹿児島厚生連病院(鹿児島県)
県民健康プラザ鹿屋医療センター(鹿児島県)
鹿児島共済会南風病院(鹿児島県)
浦添総合病院(沖縄県)
中頭病院(沖縄県)
沖縄県立南部医療センター・こども医療センター(沖縄県)
琉球大学(沖縄県)
広島赤十字・原爆病院(広島県)
松山赤十字病院(愛媛県)
宮崎県立日南病院(宮崎県)

Other administrative information
Date of disclosure of the study information
2010 Year 07 Month 14 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications http://www.ncbi.nlm.nih.gov/pubmed/26338269
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2010 Year 03 Month 29 Day
Date of IRB
Anticipated trial start date
2010 Year 04 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2010 Year 07 Month 14 Day
Last modified on
2017 Year 01 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004706

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.